A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food.

This document provides information about an ongoing clinical trial, NCT06624072, conducted by Boehringer Ingelheim. The trial aims to investigate the effects of two formulations of the drug Nerandomilast when administered in different treatment sequences. The trial is open to both male and female participants between the ages of 18 and 55 who meet certain eligibility criteria. The primary completion date for data collection is November 30, 2024. Contact details and data sharing plans are also provided. [Extracted from the article]